S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ONVO Organovo Holdings Inc

0.566

0.034 (6.39%)

Last Updated: 23:40:02

Delayed by 15 minutes

Unknown (sec Staff)

This regulatory filing also includes additional resources:
filename1.pdf

Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Aug 2024 to Sep 2024

Click Here for more Organovo Charts.

Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2023 to Sep 2024

Click Here for more Organovo Charts.

Organovo Holdings, Inc. News

Form 8-K - Current report
Saturday 10 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 10 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 8 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 6 August 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Saturday 27 July 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 25 July 2024 (2 months ago) • Edgar (US Regulatory)

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Tuesday 16 July 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Saturday 1 June 2024 (3 months ago) • Edgar (US Regulatory)

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Tuesday 21 May 2024 (4 months ago) • GlobeNewswire Inc.

More Organovo Holdings, Inc. News Articles

Australian SE All Ordina...

S&P ASX 300 Metals and M...

Commonwealth Bank Of Aus...

National Australia Bank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions